CD8A and neoplasm: Among TLR7-positive patients, those with the highest CD3–CD8 tumor–stroma index had a five-year DSS of 87.9% (95% CI 76.7–99.1) compared to 48.0% (95% CI 37.4–58.6; p < 0.001, log-rank test; Fig 3h) among patients with the lowest CD3–CD8 tumor–stroma index.